CliffBio
small molecule

AMLODIPINE BESYLATE

AMLODIPINE BESYLATE

Loss of exclusivity—loss of exclusivity
CompanyCipla →See this company's full patent-cliff portfolio

Drug detail

Brand nameAMLODIPINE BESYLATE
Active ingredientAMLODIPINE BESYLATE
StrengthEQ 5MG BASE
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalSeptember 2007
Marketing statusRX

More from Cipla

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

AMLODIPINE BESYLATE patent cliff — loss of exclusivity — | CliffBio